Press Releases Archives | Page 30 of 118

Gameto Announces New Data Demonstrating Clinical-Grade Manufacturing of In Vitro Maturation Solution for Fertility Care

May 29, 2024 By Cade Hildreth, Founder & President Leave a Comment

Manuscript demonstrates Gameto’s manufacturing process resulted in ovarian support cells of improved efficacy, quality and safety for in vitro maturation applications

NEW YORK, May 8, 2024 — Gameto, a female-led biotechnology company with a mission to redefine women’s healthcare, announced new research outlining the cellular engineering and manufacturing techniques underlying Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body. These data underscore that Gameto’s quality by design strategic product development supports the manufacturing of OSC-IVM for clinical and commercial use. [Read more…]

Further CYP-001 GvHD Clinical Data Published in Nature Medicine

May 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%

Melbourne, Australia; 22 May 2024 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.

CYP-001 is Cynata’s Cymerus™ off-the-shelf iPSC^[i]-derived MSC^[ii] product for intravenous infusion, which is being investigated as a potential immune modulating treatment. [Read more…]

AABB Releases New Resources and Initiatives For its Certified Advanced Biotherapies Professional (CABP) Program

May 9, 2024 By Cade Hildreth, Founder & President Leave a Comment

May 1, 2024, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP) credentialing program. These updates, released to make the CABP program more accessible to biotherapies professionals and organizations, include: [Read more…]

Century Therapeutics Raises $60 Million, Acquires Clade Therapeutics, and Expands Pipeline of Allogeneic, iPSC-Derived Cellular Therapies

May 5, 2024 By Cade Hildreth, Founder & President Leave a Comment

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile

Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026

Acquisition of Clade Therapeutics strengthens Century’s position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-Evasion^TM platform

Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade’s αβ iT platform spanning across cancer and autoimmune diseases

[Read more…]

SCG Cell Therapy And A*STAR Launch Joint Labs To Advance iPSC Technology For Scalable GMP Manufacturing Of Cellular Immunotherapies

April 29, 2024 By Cade Hildreth, Founder & President Leave a Comment

Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates to facilitate research leading to translation of novel cellular immunotherapies.

Launch of the joint labs builds on existing license, research collaboration and Memorandum of Understanding between SCG Cell Therapy and A*STAR.